GlassScriptPhysician profile
Daniel Lebovits
NPI 1013990936
$5,237.83
in general payments reported to CMS, 2019-2025
27 companies · $732 in 2025
The $732 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,455 · 2023: $1,249 · 2024: $802 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.96 |
| Education | $189.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.56 | 2022-2025 | |
| Janssen Biotech, INC. | $524.98 | 2022-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $506.36 | 2022-2025 | Bimzelx, Briviact, Cimzia |
| Genzyme Corporation | $480.18 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $342.99 | 2022-2025 | Ilumya |
| Galderma Laboratories, L.P. | $321.62 | 2022-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $309.53 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $240.29 | 2022-2024 | Sotyktu |
| Pfizer INC. | $210.90 | 2022-2023 | |
| Leo Pharma INC. | $167.06 | 2022-2023 | Adbry |
| Lilly USA, LLC | $164.69 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Scientific Affairs, LLC | $121.60 | 2022 | |
| Amgen INC. | $120.15 | 2023-2025 | Otezla, Otezla, Enbrel |
| Incyte Corporation | $104.78 | 2022-2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.42 | 2024-2025 | Spevigo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $91.44 | 2022 | |
| Mayne Pharma Commercial LLC | $91.05 | 2022-2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.17 | 2022-2024 | Jublia, Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $50.55 | 2023-2024 | Vtama |
| Almirall LLC | $48.45 | 2022 | |
| Epi Health, LLC | $47.23 | 2022 | |
| Biofrontera INC. | $42.62 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $31.96 | 2023 | Dupixent |
| Journey Medical Corporation | $30.78 | 2022 | |
| Arcutis Biotherapeutics, INC. | $30.04 | 2024 | Zoryve |
| Paratek Pharmaceuticals, INC. | $18.52 | 2023 | Nuzyra |
| Organon LLC | $7.91 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lebovits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.